Research Article
Atul A. Bodkhe, Sagar Rase, Pr
Abstract
This study was carried out to develop an oral colon specific, tablet to achieve site specific release of ornidazole and ciprofloxacin hydrochloride. The basic design consists of coating of ornidazole with eudragit to form microgranules and compressing the ciprofloxacin hydrchloride powder into a tablet to release the ciprofloxacin hydrochloride in the stomach and finally with film coating for stability and esthetic appeal. The ornidazole was enteric coated, so that the variability in gastric emptying time can be overcome and a colon-specific release can be achieved. The ornidazole microgranules were prepared with Eudragit®L-100, by varying drug to polymer ratio and evaluated for the particle size, drug content and in vitro release profile and from the obtained results; one better formulation was selected for further fabrication of tablet. The aim behind developing this formulation was that when any patient suffers from amebiasis, can be treated with conventional ornidazole tablet for instant release but after that the organism resides at the lower GIT(colon) in the dormant phase and many times relapse of the condition occur with the patient. Thus it can be avoided by targeting the drug at the colon after the initial treatment.